Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET) (AIDANET AI)

Bolus Priming (BP) based on Artificial Intelligence (AI) learning of meal patterns, added to our established Automated insulin delivery as Adaptive Network (AIDANET) algorithm and running on iPhone Diabetes Assistant (iDiAs) phone wirelessly connected to Tandem Mobi insulin pump and Dexcom Continuous Glucose Monitor (CGM).

Study Overview

• Status: Not yet recruiting
• Conditions: Type 1 Diabetes Mellitis
• Intervention / Treatment: Device: Hybrid Closed Loop (HCL) x 2 weeks; Device: AIDANET x 2 weeks; Device: AIDANET AI x 4 weeks

Detailed Description

A randomized cross-over trial assessing glycemic control on AIDANET equipped with its standard bolus vs AIDANET AI. A secondary comparison of AIDANET AI vs a current commercial Hybrid Closed Loop (HCL) system is planned as well.

Following enrollment and screening, participants will be randomized 1:1 to two 8-week sequences: Group A participants will continue to use their home Hybrid closed loop (HCL) system for 2 weeks, then switch to AIDANET for two weeks, and the switch to AIDANET AI for another 4 weeks. Group B participants will begin with 4 weeks of AIDANET AI, then switch to AIDANET for 2 weeks and then revert to their home HCL systems for the last 2 weeks of the study (Figure 1). The last two weeks of the 4-week AIDANET AI session will be used for analysis, comparing standard Ambulatory Glucose Profile (AGP) metrics across AIDANET vs AIDANET AI, with primary outcome Time in Range (TIR) (70-180 mg/dL) during the day. Secondary analyses will compare AIDANET AI 2-week AGP to HCL AGP metrics. Both analyses use randomized crossover design.

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Carlene Alix; Phone Number: 434-249-8961; Email: UAX8YX@uvahealth.org
• Study Contact Backup: Name: Laura Kollar, RN; Phone Number: 434-982-6479; Email: LLK7M@uvahealth.org

Study Locations

• United States
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • University of Virginia Center for Diabetes Technology
      • Sub-Investigator: Boris Kovatchev, PhD
      • Sub-Investigator: Anas El Fathi, PhD
      • Sub-Investigator: Marc Breton, PhD
      • Sub-Investigator: Mark DeBoer, MD
      • Sub-Investigator: Samina Afreen, MD
      • Contact: Sue Brown, MD; Phone Number: 4349820602; Email: sab2f@uvahealth.org
      • Sub-Investigator: Kimberly Driscoll, PhD
      • Sub-Investigator: Meryem Karagoz, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥18.0 years old at time of consent
2. Clinical diagnosis, based on investigator assessment, of Type 1 Diabetes (T1D) for at least one year.
3. Currently using an automated insulin delivery (AID) system.
4. Willingness to switch to use a commercially approved personal insulin (e.g., lispro or aspart, or biosimilar approved products) within the study pump as directed by the study team.
5. Has one or more supportive companions knowledgeable about emergency procedures for severe hypoglycemia and able to contact emergency services and study staff that either live with participant or located within approximately 30 minutes of participant and able to locate participant in the event of an emergency.
6. Participant not currently known to be pregnant or breastfeeding.
7. If participant can become pregnant, they must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
8. Willingness to use the study AIDANET system (CGM, insulin pump, and phone) during the study period.
9. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial.
10. Willingness to participate in all study procedures.
11. Access to internet at home and willingness to upload data during the study as needed.
12. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol.
13. Participant is proficient in reading and writing English.

Exclusion Criteria:

1. Plans to start a new non-insulin glucose-lowering agent (e.g., Glucagon-like peptide-1 (GLP-1) receptor agonists, Symlin, DPP-4 inhibitors, sulfonylureas). Participants may be on a stable dose of such an agent for at least the past month.
2. Current use of an sodium-glucose transport protein 2 (SGLT-2) or SGLT-1/2 inhibitor due to risk of euglycemic diabetic ketoacidosis (DKA).
3. Hemophilia or any other bleeding disorder.
4. History of severe hypoglycemic events with seizure or loss of consciousness in the last 12 months.
5. History of DKA event in the last 12 months.
6. Unstable Stage 4 chronic renal disease or currently on peritoneal or hemodialysis.
7. Currently being treated for adrenal insufficiency.
8. Currently being treated for a seizure disorder.
9. Hypothyroidism or hyperthyroidism that is not adequately treated.
10. Use of oral or injectable steroids at the time of enrollment or within the last 2 weeks.
11. Planned surgery during the study period that results in prolonged disconnection from study devices.
12. Known ongoing adhesive intolerance that is not well managed.
13. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk.
14. Participation in another interventional trial at the time of enrollment.
15. Participant with a direct supervisor involved in the conduct of the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GROUP A: 2 weeks HCL, 2 weeks AIDANET, and 4 weeks AIDANET AI; Group A participants will continue to use their home HCL system for 2 weeks, then switch to AIDANET for two weeks, and the switch to AIDANET AI for another 4 weeks.	Device: Hybrid Closed Loop (HCL) x 2 weeks; During the HCL session, participants will be using their own HCL systems for 2-weeks.; Device: AIDANET x 2 weeks; Participant will use the AIDANET algorithm on the Mobi system with the standard Bolus Priming System (BPS) automated bolus that does not require announcement of meals.; Device: AIDANET AI x 4 weeks; Participant will use the AIDANET algorithm with the addition of the Bolus Priming (BP) based on AI learning of meal patterns.
Experimental: GROUP B: 4 weeks AIDANET AI, 2 weeks AIDANET, and 2 weeks HCL; Group B participants will begin with 4 weeks of AIDANET AI, then switch to AIDANET for 2 weeks and then revert to their home HCL systems for the last 2 weeks of the study	Device: Hybrid Closed Loop (HCL) x 2 weeks; During the HCL session, participants will be using their own HCL systems for 2-weeks.; Device: AIDANET x 2 weeks; Participant will use the AIDANET algorithm on the Mobi system with the standard Bolus Priming System (BPS) automated bolus that does not require announcement of meals.; Device: AIDANET AI x 4 weeks; Participant will use the AIDANET algorithm with the addition of the Bolus Priming (BP) based on AI learning of meal patterns.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time in Range (TIR) 70-180 mg/dL for 2-week free-living at home periods on AIDANET vs AIDANET AI.	The last two weeks of the 4-week AIDANET AI session will be used for analysis, comparing standard Ambulatory Glucose Profile metrics across AIDANET vs AIDANET AI, with primary outcome TIR (70-180 mg/dL) during the day.	two weeks

Collaborators and Investigators

• Sponsor: Sue Brown
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Tandem Diabetes Care, Inc.
• Investigators: Principal Investigator: Sue Brown, MD, University of Virginia Center for Diabetes Technology

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2026
• Primary Completion (Estimated): April 30, 2027
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: March 30, 2026
• First Submitted That Met QC Criteria: April 3, 2026
• First Posted (Actual): April 8, 2026

Study Record Updates

• Last Update Posted (Actual): April 8, 2026
• Last Update Submitted That Met QC Criteria: April 3, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Type 1 Diabetes (T1D); Hybrid Closed Loop (HCL); Bolus Priming System (BPS); Fully Closed Loop (FCL); Artificial-Intelligence (AI); Mobi insulin pump; iPhone Diabetes Assistant (iDiAs); Automated insulin delivery as Adaptive Network (AIDANET) algorithm; Mobi Research App (MRA)
• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Autoimmune Diseases; Immune System Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 1
• Other Study ID Numbers: 303428; R01DK133148 (U.S. NIH Grant/Contract)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes